Compile Data Set for Download or QSAR
Report error Found 11 Enz. Inhib. hit(s) with all data for entry = 9074
TargetTyrosine-protein kinase BTK(Human)
Crystalgenomics

US Patent
LigandPNGBDBM340036(US9758508, Compound 17 | 1-(3-chloro-2,6-difluorop...)
Affinity DataIC50: 0.0500nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Crystalgenomics

US Patent
LigandPNGBDBM340037(US9758508, Compound 18 | 1-(2-chloro-3,6-difluorop...)
Affinity DataIC50: 0.0700nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Crystalgenomics

US Patent
LigandPNGBDBM340031(US9758508, Compound 7 | 1-{3-fluoro-4-[7-(5-methyl...)
Affinity DataIC50: 0.100nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Crystalgenomics

US Patent
LigandPNGBDBM340033(US9758508, Compound 12 | 1-{3-fluoro-4-[7-(5-methy...)
Affinity DataIC50: 0.280nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Crystalgenomics

US Patent
LigandPNGBDBM340032(US9758508, Compound 9 | 1-{3-fluoro-4-[7-(5-methyl...)
Affinity DataIC50: 0.400nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Crystalgenomics

US Patent
LigandPNGBDBM340030(US9758508, Compound 4 | 1-(2-chloro-6-fluoro-pheny...)
Affinity DataIC50: 0.900nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Crystalgenomics

US Patent
LigandPNGBDBM340039(US9758508, Compound 20 | 1-{3-fluoro-4-[7-(5-methy...)
Affinity DataIC50: 0.900nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Crystalgenomics

US Patent
LigandPNGBDBM340029(US9758508, Compound 3 | 1-(2,6-difluoro-phenyl)-3-...)
Affinity DataIC50: 1nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Crystalgenomics

US Patent
LigandPNGBDBM340038(US9758508, Compound 19 | 1-(4-chloro-2,6-difluoro-...)
Affinity DataIC50: 4nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Crystalgenomics

US Patent
LigandPNGBDBM340035(US9758508, Compound 15 | 1-(4-cyano-3-fluorophenyl...)
Affinity DataIC50: 5nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Crystalgenomics

US Patent
LigandPNGBDBM340034(US9758508, Compound 14 | 1-(3,4-difluoro-phenyl)-3...)
Affinity DataIC50: 5.60nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2020
Entry Details
Go to US Patent